Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Allogeneic peripheral blood stem cell transplantation for standard risk leukemia: experience of Ibni Sina Hospital
Autore:
Arslan, O; Coskun, HS; Arat, M; Celebi, H; Ozcan, M; Gurman, G; Ustun, C; Demirer, T; Akan, H; Ilhan, O; Konuk, N; Beksac, M; Uysal, A; Koc, H;
Indirizzi:
Ankara Univ, Sch Med, Ibni Sina Hosp, Dept Hematol Oncol,Bone Marrow Transplantat Unit, TR-06100 Ankara, Turkey Ankara Univ Ankara Turkey TR-06100 plantat Unit, TR-06100 Ankara, Turkey
Titolo Testata:
BONE MARROW TRANSPLANTATION
fascicolo: 12, volume: 25, anno: 2000,
pagine: 1229 - 1232
SICI:
0268-3369(200006)25:12<1229:APBSCT>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; VERSUS-HOST DISEASE; PROGENITOR CELLS; ALLO-PBPCT; GRAFT; MARROW; DONORS; GVHD;
Keywords:
allogeneic peripheral blood stem cell transplantation; standard risk leukemia; graft-versus-host disease;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Arslan, O Ankara Univ, Sch Med, Ibni Sina Hosp, Dept Hematol Oncol,Bone Marrow Transplantat Unit, TR-06100 Ankara, Turkey Ankara Univ Ankara TurkeyTR-06100 it, TR-06100 Ankara, Turkey
Citazione:
O. Arslan et al., "Allogeneic peripheral blood stem cell transplantation for standard risk leukemia: experience of Ibni Sina Hospital", BONE MAR TR, 25(12), 2000, pp. 1229-1232

Abstract

Fifty-three patients with standard risk leukemia who underwent allogeneic peripheral blood stem cell transplantation (alloPBSCT) from their HLA-identical siblings were analyzed for engraftment, incidence and severity of GVHD, and relapse rate. Standard risk leukemia was defined as AML in first complete remission or CML in first chronic phase within the first year after diagnosis. The median age was 34.5 years (range 13-47), Stem cells were mobilized by using 10 mu g/kg G-CSF subcutaneously for 5 days. A median of 5.7 (2.1-21.4) x 10(6)/kg CD34(+) cells was collected over a median of 2 (range 1-5) apheresis procedures. Cyclosporin A (CsA) plus short-course MTX were used for GVHD prophylaxis. Recovery to granulocytes >0.5 x 10(9)/1 and platelets >20 x 10(9)/l occurred at a median of day +13 (range 8-32) and +13 (range 8-51), respectively. Day +100 transplant-related mortality was 13.2% (7/53). Acute GVHD occurred in 20 of 49 (41%) evaluable patients and only six(12.3%) of them had severe disease (grade III-IV). Chronic GVHD occurred in 30 of 42 (71.4%) evaluable patients. Relapse rate at 2 years was 7.5%. The median overall and leukemia-free survivals were 22 (4-44) and 20 (3-44) months, respectively. Estimated 4 year leukemia-free and overall survival rates were 60% and 62%, respectively. In conclusion, alloPBSCT in standard risk leukemia seems to be associated with a low relapse rate and no increasedrisk of acute GVHD, but there is a trend for higher incidence of cGVHD.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/04/20 alle ore 07:23:03